Clinical Trials in Nephrology: An Updated Systematic Review of ClinicalTrials.gov

Reem A. Mustafa, MD, PhD, MPH; Nedaa Husainat, MD; Mohamad Kalot, MD; Abdallah El Aaylli, MD; Adnan Shaaban, MD; Laith Numan, MD; Mohammed Al-Khatib, MD; Nigar Sekercioglu, MD, Raabia Nizamuddin, MD, Julie Ishida, MD, Melissa West; Sheri Tibbs; Uptal Patel, MD; Jula Ingrig MD.

1 University of Kansas, Kansas City, KS, United States, 2 Lebanese American University, Beirut, Lebanon, 3 University of Missouri, Kansas City, MO, United States, 4 University of Minnesota, Minneapolis, MN, United States, 5 McMaster University, Hamilton, ON, Canada, 6 Gilead Sciences, San Francisco, CA, United States, 7 American Society of Nephrology, Washington, DC, United States, 8 Duke University, Durham, NC, United States, 9 Gilead Sciences, Inc., Foster City, CA, United States, 10 IQVIA, UC Irvine, Duke University, Yorba Linda, CA, United States.

Introduction

• Previously published reviews highlighted low rates and poor quality of clinical trials in nephrology compared to other specialties.
• In this review we assess time trends in quality and quantity of nephrology trials.

Methodology

• We conducted a systematic review among Nephrology trials registered on ClinicalTrials.gov from inception to November 2018.
• Two independent reviewers assessed every trial and extracted data about major category, population and outcomes.
• After downloading a database of 288,515 interventional registered trials, the Nephrology data set was restricted to studies that includes one of 154 nephrology terms (both Medical Subject Headings [MeSH] and non-MeSH).
• Reviewers screened 5412 records and included 4959 studies in data analysis. We grouped the included trials into 3 eras. Era-1 [09/30-1982-08/31/2010]; Era-2 [09/01/2010-08/31/2014]; Era-3 [09/01/2014-12/31/2018].

Results

- Era 3 has more randomized, blinded and large trials.
- Drug trials per era has decreased while device and behavioral interventions increased.
- There has been a decrease in NIH and industry funded studies.
- There has been some improvement in quality and a promising trend in trials for devices, behavioral interventions and initiatives like the Kidney Health Initiative (KHI) are likely to have contributed to the improvement in quality and quantity of nephrology trials.
- Highlighting specific areas that are deficient in nephrology trials is likely to have increased contribution in those areas.

Discussion

- There has been some improvement in quality and a promising trend in trials for devices, behavioral interventions and initiatives like the Kidney Health Initiative (KHI) are likely to have contributed to the improvement in quality and quantity of nephrology trials.

References

- Chatzimanouil MKT, Wilkens L, Anders H-J. Quantity and Reporting Quality Initiatives like the Kidney Health Initiative (KHI) are likely to have contributed to the improvement in quality and quantity of nephrology trials. Fostering innovation, advancing patient safety: the kidney health initiative. 2013;63(5):771-80.

Clinical Trial Major Category

Table 1. Trial Characteristics

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomization</td>
<td>77.4%</td>
<td>84.5%</td>
<td>82.6%</td>
</tr>
<tr>
<td>Blinding</td>
<td>30.3%</td>
<td>34.1%</td>
<td>34.7%</td>
</tr>
<tr>
<td>1000 Patient</td>
<td>1.5%</td>
<td>2%</td>
<td>4.1%</td>
</tr>
<tr>
<td>NIH funded</td>
<td>8%</td>
<td>4.5%</td>
<td>6.6%</td>
</tr>
<tr>
<td>Industry Funded</td>
<td>45.3%</td>
<td>42.8%</td>
<td>32.2%</td>
</tr>
<tr>
<td>Drug Intervention</td>
<td>73.5%</td>
<td>64.5%</td>
<td>57.2%</td>
</tr>
<tr>
<td>Device Intervention</td>
<td>6%</td>
<td>8.9%</td>
<td>10.7%</td>
</tr>
<tr>
<td>Behavioral Intervention</td>
<td>2.7%</td>
<td>4%</td>
<td>6.2%</td>
</tr>
<tr>
<td>Glomerular disease</td>
<td>5.8%</td>
<td>6%</td>
<td>7.5%</td>
</tr>
</tbody>
</table>

Table 3. Distribution of nephrology trials.

- There is an increase in living donor recipient trials [Era 1: 11.4%; Era 2: 8.6%; Era 3: 23.6%].

Figure 1. Number of registered nephrology trials on ClinicalTrials.gov

Figure 2. Major Categories for reporting on clinicaltrials.gov

Figure 3. Distribution of nephrology trials.